REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage firm that goals to set up gene remedy as a brand new customary of take care of extremely prevalent ocular illnesses, immediately introduced that Laurent Fischer, M.D., president and chief government officer of Adverum Biotechnologies, will current at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022.
The on-demand webcast company presentation could also be accessed beneath Events and Presentations in the Investors part of Adverum’s web site. A replay of the webcast shall be out there on the web site for 90 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage firm that goals to set up gene remedy as a brand new customary of take care of extremely prevalent ocular illnesses with the aspiration of creating useful cures to restore imaginative and prescient and forestall blindness. Leveraging the analysis capabilities of its proprietary, intravitreal (IVT) platform, Adverum is creating sturdy, single-administration therapies, designed to be delivered in physicians’ places of work, to remove the want for frequent ocular injections to deal with these illnesses. Adverum is evaluating its novel gene remedy candidate, ixoberogene soroparvovec (Ixo-vec, previously referred to as ADVM-022), as a one-time, IVT injection for sufferers with neovascular or moist age-related macular degeneration. By overcoming the challenges related to present remedy paradigms for these debilitating ocular illnesses, Adverum aspires to remodel the customary of care, protect imaginative and prescient, and create a profound societal impression round the globe. For extra data, please go to www.adverum.com.
Forward-looking Statements
Statements contained in this press launch relating to occasions or outcomes which will happen in the future are “forward-looking statements” inside the that means of the Private Securities Litigation Reform Act of 1995. Actual outcomes may differ materially from these anticipated in such forward-looking statements on account of numerous dangers and uncertainties, together with dangers inherent to, with out limitation: Adverum’s novel expertise, which makes it troublesome to predict the timing of graduation and completion of medical trials; regulatory uncertainties; enrollment uncertainties; the outcomes of early medical trials not all the time being predictive of future medical trials and outcomes; and the potential for future problems or negative effects in reference to use of Ixo-vec. Additional dangers and uncertainties dealing with Adverum are set forth beneath the caption “Risk Factors” and elsewhere in Adverum’s Securities and Exchange Commission (SEC) filings and reviews, together with Adverum’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 11, 2022. All forward-looking statements contained in this press launch communicate solely as of the date on which they had been made. Adverum undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date on which they had been made.
Corporate & Investor Inquiries
Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: [email protected]
Media
Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: [email protected]
